Link Between Plasma Aldosterone Levels and Cardiovascular Disease Risk in Patients with Hypertension: A Cohort Analysis - Scorecard - MDSpire

Link Between Plasma Aldosterone Levels and Cardiovascular Disease Risk in Patients with Hypertension: A Cohort Analysis

  • By

  • Lin Gan

  • Nanfang Li

  • Mulalibieke Heizhati

  • Hui Wang

  • Ling Yao

  • Li Cai

  • Shasha Liu

  • Jing Hong

  • Delian Zhang

  • April 23, 2026

  • 0 min

Share

Clinical Scorecard: Link Between Plasma Aldosterone Levels and Cardiovascular Disease Risk in Patients with Hypertension: A Cohort Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsRevise to include specific mechanisms of PAC's role in CVD as detailed in the study.
Target Population
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • S
      • p
      • e
      • c
      • i
      • f
      • y
      • r
      • e
      • c
      • o
      • m
      • m
      • e
      • n
      • d
      • e
      • d
      • i
      • n
      • t
      • e
      • r
      • v
      • a
      • l
      • s
      • f
      • o
      • r
      • P
      • A
      • C
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • i
      • n
      • g
      • .

      Risks

        Patient & Prescribing Data

        List specific MR antagonists and their clinical applications.

        Clinical Best Practices

        • evidence

        References

        Original Source(s)

        Link Between Plasma Aldosterone Levels and Cardiovascular Disease Risk in Patients with Hypertension: A Cohort Analysis

        • by Lin Gan, Nanfang Li, Mulalibieke Heizhati, Hui Wang, Ling Yao, Li Cai, Shasha Liu, Jing Hong, Delian Zhang

        • April 23, 2026

        Related Content

        Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care

        Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes

        FDA Monthly Preview: Key June Decisions to Watch

        Several FDA decisions across multiple specialties are expected this month.